Victory Capital Management Inc. Has $415,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Victory Capital Management Inc. trimmed its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 72.5% during the fourth quarter, HoldingsChannel reports. The fund owned 5,208 shares of the company’s stock after selling 13,726 shares during the quarter. Victory Capital Management Inc.’s holdings in Axsome Therapeutics were worth $415,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC lifted its position in Axsome Therapeutics by 30.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 6,741 shares of the company’s stock valued at $471,000 after acquiring an additional 1,558 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Axsome Therapeutics by 4.3% in the third quarter. Bank of New York Mellon Corp now owns 168,006 shares of the company’s stock worth $11,742,000 after purchasing an additional 6,920 shares during the period. Fifth Third Bancorp lifted its stake in Axsome Therapeutics by 100.0% during the third quarter. Fifth Third Bancorp now owns 400 shares of the company’s stock worth $28,000 after purchasing an additional 200 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Axsome Therapeutics in the third quarter worth about $367,000. Finally, Barclays PLC grew its stake in shares of Axsome Therapeutics by 22,927.4% in the third quarter. Barclays PLC now owns 16,810 shares of the company’s stock worth $1,175,000 after purchasing an additional 16,737 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Price Performance

AXSM stock opened at $75.19 on Friday. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of -11.79 and a beta of 1.13. The company has a quick ratio of 3.09, a current ratio of 3.20 and a debt-to-equity ratio of 1.25. Axsome Therapeutics, Inc. has a fifty-two week low of $55.02 and a fifty-two week high of $98.40. The business has a 50 day moving average price of $74.37 and a 200 day moving average price of $76.62.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, February 20th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.48. The business had revenue of $71.53 million during the quarter, compared to analysts’ expectations of $70.38 million. Axsome Therapeutics had a negative return on equity of 87.17% and a negative net margin of 118.07%. Equities research analysts anticipate that Axsome Therapeutics, Inc. will post -4.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on AXSM. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, April 10th. Royal Bank of Canada upped their target price on Axsome Therapeutics from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Mizuho cut their target price on shares of Axsome Therapeutics from $109.00 to $106.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Truist Financial reissued a “buy” rating and issued a $150.00 price target on shares of Axsome Therapeutics in a report on Tuesday, March 26th. Finally, UBS Group assumed coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 6th. They issued a “buy” rating and a $111.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $121.92.

Insider Activity

In other news, Director Roger Jeffs sold 29,976 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the transaction, the director now directly owns 120,756 shares in the company, valued at approximately $8,416,693.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Roger Jeffs sold 29,976 shares of Axsome Therapeutics stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the sale, the director now owns 120,756 shares in the company, valued at $8,416,693.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $77.24, for a total value of $1,904,892.88. The disclosure for this sale can be found here. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.